tirzepatide
PulseAugur coverage of tirzepatide — every cluster mentioning tirzepatide across labs, papers, and developer communities, ranked by signal.
- 2026-05-11 product_launch ShengNuo Bio's tirzepatide API successfully completed its filing with the US FDA. source
6 day(s) with sentiment data
-
GLP-1 Drugs Boost Women's Employment More Than College Degrees, Study Finds
A study from Harvard University, published by the National Bureau of Economic Research, suggests that GLP-1 drugs, such as Ozempic and Wegovy, have a greater impact on increasing women's employment rates than obtaining …
-
GLP-1 drugs show surprising benefits beyond weight loss
GLP-1 medications, commonly known for weight loss and type 2 diabetes treatment, are demonstrating a range of surprising health benefits beyond their initial applications. Recent trials indicate these drugs can protect …
-
Novo Nordisk faces growth challenges after Wegovy success, rival Eli Lilly gains ground
Novo Nordisk, once Europe's most valuable company due to the success of its weight-loss drugs Ozempic and Wegovy, is facing challenges in developing new blockbuster treatments. Its rival, Eli Lilly and Company, has gain…
-
Eli Lilly's Obesity Drugs Fuel 48% Revenue Growth, Retatrutide Trials Show Promise
Eli Lilly and Company reported a significant increase in its second-quarter revenue, reaching $23 billion, a 48% year-over-year growth. This surge was primarily driven by its GLP-1 drugs, Mounjaro and Zepbound, which ge…
-
GLP-1 drugs like Ozempic may cause unlisted side effects, study finds
New research indicates that GLP-1 medications like Ozempic and Wegovy may have side effects not listed on their labels. A study analyzing Reddit posts found that nearly half of semaglutide and tirzepatide users reported…
-
Medicare launches GLP-1 bridge program for weight loss drugs
The Medicare Bridge program, initiated by the Trump administration, offers eligible seniors and disabled individuals access to certain GLP-1 weight loss medications for a flat $50 monthly co-payment. This demonstration …
-
FDA reviews popular peptides amid safety and efficacy concerns · 2 sources tracked
The U.S. Food and Drug Administration (FDA) is set to review seven peptides for potential approval for compounding by pharmacies. These peptides, including BPC-157, TB-500, and Semax, are popular in longevity and wellne…
-
Geely Deep Blue plans share buyback amid other industry news
Geely Deep Blue announced a plan to repurchase shares worth 50 million to 100 million yuan, with the repurchase price not exceeding 25 yuan per share. This move aims to maintain the company's value and protect sharehold…
-
Novo Nordisk sues Eli Lilly over drug ad claims; China insurance experts discuss AI
Novo Nordisk has filed a lawsuit against Eli Lilly and Company in a U.S. federal court. The lawsuit alleges that Eli Lilly's advertisements for its weight-loss drug Zepbound and diabetes drug Mounjaro are misleading. Se…
-
Autoimmune disease therapies boom amid VC investment; OpenAI targets healthcare
The field of autoimmune disease therapies is experiencing a significant boom, with projected revenues for drugs like AbbVie's Skyrizi expected to reach $33 billion by 2032. This growth is driven by scientific breakthrou…
-
Medicare launches $50/month GLP-1 weight loss drug program
The Trump administration has launched a temporary Medicare Bridge program to provide some beneficiaries with access to popular weight loss medications like tirzepatide and semaglutide for a flat $50 monthly co-payment. …
-
Eli Lilly invests $40M in AI drug firm Absci for baldness treatment
Eli Lilly has invested $40 million in Absci, a generative AI drug discovery company, as part of a larger $100 million stock offering. Absci utilized AI to design ABS-201, an injectable antibody targeting a hormone recep…
-
GLP-1 drugs disrupt diet trends, fueling protein-focused food market
GLP-1 medications are fundamentally altering the food industry, according to David Protein CEO Peter Rahal. He states that traditional diet trends are becoming obsolete as people increasingly turn to these drugs for wei…
-
GLP-1 drugs fuel luxury spending but expose fashion's size inclusivity gap
The luxury sector is experiencing a complex shift influenced by the increasing adoption of GLP-1 weight-loss medications. While overall sector growth has seen a slight dip, these medications are driving consumption as i…
-
GLP-1 weight-loss drugs drive major climate impact by cutting food demand
The widespread adoption of GLP-1 medications for weight loss is having a significant, albeit unintended, impact on the climate by reducing demand for carbon-intensive foods. As more Americans use drugs like semaglutide …
-
Government healthcare cost projections struggle with GLP-1 drug spending
Government healthcare cost projections for GLP-1 medications like Ozempic and Mounjaro are proving difficult to accurately forecast. Agencies like CMS and CBO rely on historical data and assumptions that may not account…
-
France to reimburse anti-obesity drugs for first time in EU
France is set to become the first European Union country to reimburse anti-obesity medications for severely obese patients starting mid-June. The government estimates this initiative will cost approximately €100 million…
-
GLP-1 drugs show anti-inflammatory benefits beyond weight loss
GLP-1 medications like Ozempic and Wegovy, known for weight loss, are showing promise in treating inflammation and tissue damage, particularly in osteoarthritis. A study in Cell Metabolism found semaglutide reduced infl…
-
GLP-1 drugs may reduce cancer progression, new study suggests
New research presented at the American Society of Clinical Oncology meeting suggests that GLP-1 medications, commonly used for diabetes and weight loss, may also reduce the progression of certain cancers. A study analyz…
-
ShengNuo Bio's tirzepatide API clears US FDA filing
ShengNuo Bio announced that its tirzepatide active pharmaceutical ingredient has completed its filing with the US FDA, making it available for use by drug manufacturers. This GLP-1/GIP dual receptor agonist is intended …